UNSPSC 41131731: Thromboplastin generation test

In this classification a thromboplastin generation test is a device used to detect and identify coagulation factor deficiencies and coagulation inhibitors US FDA regulates Thromboplastin generation test under 21 CFR 864.7900 and under FDA product code GKQ.

UNSPSC 41131731 Thromboplastin generation test is a Commodity code that sees very limited recent state and local procurement activity directly aligned with its nominal scope. The eight recent opportunities tagged to this code span forensic drug testing, employment physicals and drug screening, breath alcohol testing equipment, and naloxone procurement — none of which center on thromboplastin or coagulation testing. The single opportunity most plausibly related to the code's stated function is Pinellas County, Florida's procurement of certified drug reference materials and laboratory standards for forensic toxicology and seized-drug analysis (Invitation to Quote #26-0305-ITQ, response due April 23, 2026). The remaining opportunities represent clear coding mismatches: Collin County's RFP for offender drug testing services, Benton County, Oregon's RFP for urinalysis testing, and City Colleges of Chicago's RFP for employment screening and drug testing services all solicit specimen collection and immunoassay-based drug panels rather than coagulation assays. Similarly, Nevada's two IFBs for Intoxilyzer 9000 breath alcohol testing devices and Seminole County's procurement of naloxone and drug deactivation systems fall outside the code's scope entirely.

State and local procurement under this code shows no meaningful recent activity. The issuing bodies represented — Collin County and Benton County in Texas and Oregon, Seminole County and Pinellas County in Florida, Clay County and Collier County in Florida, City Colleges of Chicago, and Nevada's Department of Public Safety — are pursuing drug testing, medical screening, and forensic lab equipment rather than thromboplastin generation assays used in coagulation studies or clinical pathology. No vendor should prioritize pursuit under this code based on current state and local solicitation patterns; the coding appears to reflect administrative categorization errors rather than genuine procurement demand for thromboplastin testing services.